New Delhi: Pharmaceuticals major Zydus Group on Wednesday announced receipt of approval from the US Food and Drug Administration (FDA) to sell chronic pain reliever morphine sulfate tablets.
"The product used in treatment of chronic pain or cancer related pain will be manufactured at Nesher Pharmaceuticals (USA) LLC, located at St Louis," Cadila Healthcare, a part of Zydus group, said in a filing to the BSE.
A subsidiary of Zydus Pharmaceuticals Inc, Nesher, has considerable expertise in niche therapies with development or products barrier, such as controlled release medications, it added.
Shares in Cadila Healthcare, on Wednesday, ended 1.6 per cent higher at Rs 1825.45 apiece on the BSE.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
